Rare cancer diagnoses surge dramatically among millennials and Gen X
A rare type of cancer is growing among millennials and members of Generation X, new research shows.
Diagnoses of appendix cancer have tripled in the U.S. for people born between 1976 and 1984 — and it has quadrupled for those born between 1981 and 1989.
The study was published on Monday in the Annals of Internal Medicine.
Common Menopause Medication Might Prevent Breast Cancer While Treating Hot Flashes
Researchers from the Vanderbilt University Medical Center analyzed data from the National Cancer Institute's Surveillance, Epidemiology and End Results (SEER) Program to arrive at these findings.
"When you take these alarming rates that we are seeing for appendiceal cancer across generations, together with the fact that one in every three patients diagnosed with appendiceal cancer is diagnosed under the age of 50, these point to a timely need for everyone to be aware of the signs and symptoms of appendix cancer," said lead author Andreana Holowatyj, PhD, assistant professor of Medicine at Vanderbilt University Medical Center and Vanderbilt-Ingram Cancer Center, in a press release from the university.
Read On The Fox News App
Fda Approves First Ai Tool To Predict Breast Cancer Risk
Cancer of the appendix is rare, affecting only about one or two people per million each year in the U.S., according to the National Cancer Institute (NCI). Even so, doctors emphasize the importance of seeking medical attention if symptoms emerge.
"Ruling out the possibility of an appendix cancer diagnosis, or diagnosing it early, is important for this cancer as we continue to learn what factors may be contributing to this worrisome trend," Holowatyj said.
Appendiceal cancer forms in the appendix, which is a small organ located in the lower right abdomen.
There are two main types: epithelial appendiceal cancer, which involves the cells of the lining of the appendix, and neuroendocrine appendiceal cancer, which results from the growth of neuroendocrine (carcinoid) tumors of the appendix, the NCI states.
In early stages of the disease, most people do not notice symptoms.
As the cancer progresses, common symptoms include pain, a bloated feeling, a mass in the abdomen, nausea and vomiting, and sudden feelings of fullness while eating, according to the above source.
Common treatments for this type of cancer include surgery to remove the appendix and any other affected organs, as well as chemotherapy to kill any metastasized cancer cells.
Based on the study findings, the researchers are calling for increased awareness among both the public and the medical community.
Click Here To Sign Up For Our Health Newsletter
"As incidence rates in younger generations are often indicative of future disease burden, these results support the need for histology-specific investigations of appendiceal adenocarcinoma, as well as increased education and awareness of appendiceal adenocarcinomas among healthcare providers and the public," the study stated.
There are no standard screening guidelines or risk factors for appendix cancer, which means up to half of diagnoses occur after the disease has already spread, according to the researchers.
Five-year survival rates for appendix cancer range from 10% to 63%.
For more Health articles, visit www.foxnews.com/health
The new study received funding from the Appendix Cancer Pseudomyxoma Peritonei (ACPMP) Research Foundation and the National Institutes of Health.Original article source: Rare cancer diagnoses surge dramatically among millennials and Gen X
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Bloomberg
3 hours ago
- Bloomberg
NATO Gets New Tools to Monitor Ukraine And the Eastern Flank
NATO is expanding its satellite surveillance capacities to scan large swaths of land, enabling the alliance to monitor military movements in Ukraine and on Russia's borders with its eastern members, top commander Pierre Vandier said. Vandier told Bloomberg News the new tool will for the first time allow the alliance to observe 'huge areas,' allowing it to observe maneuvers, troop movements and battlefield operations.
Yahoo
15 hours ago
- Yahoo
This Alarming COVID Symptom Is Everywhere With The Latest Variant. We Asked Experts What You Need To Know.
A positive COVID-19 test result is not something that anyone wants to see — but now there may be an extra reason to avoid getting sick. COVID infections cause miserable symptoms such as fever, fatigue, congestion and more. Now, though, some people infected with COVID in China are reporting a very sore throat that's been nicknamed 'razor blade throat.' According to Google trends data, people throughout the U.S. are now, too, worried about this scary-sounding symptom and are searching for things like 'new covid variant painful symptom' and 'covid razor throat.' Just how worried do you need to be about a super-painful sore throat during a COVID infection? Below, doctors weigh in on the supposed 'razor blade' sore throat symptom: Some people with COVID are reporting a 'razor blade throat,' but you don't need to panic. It's nothing new. Related: I Was Widowed At 29. Then An Unexpected Phone Call Led Me To Discover My Husband's Affairs. 'In the past, as new variants have come on the scene, there almost invariably have been questions about distinctive symptoms, and after a while, when you gather a lot of data, turns out not to be the case — all of these symptoms have occurred before,' said Dr. William Schaffner, a professor of preventive medicine in the department of health policy at Vanderbilt University Medical Center in Nashville, Tennessee. Meaning, the circulating COVID variants tend to produce the same sort of symptoms and disease as the ones from years ago, Schaffner added. 'Although the more recent variants, these omicron variants, are less severe,' he said. A very sore throat isn't specific to the circulating COVID variants, said Dr. Carrie Horn, the chief medical officer and chief of the division of hospital and internal medicine at National Jewish Health in Colorado. Instead, it's a symptom that has been associated with COVID infections for a while, Horn said. Schaffner had not heard of the 'razor blade' sore throat symptom particularly, but has heard of people having a severe sore throat with COVID infections. While some people can have a very sore throat that could be described as razor-like, it doesn't mean it's going to happen to everyone — and it also isn't some new, scary symptom that is associated with new COVID infections. There is not one outstanding COVID symptom that marks an infection, said Dr. Mark Burns, an infectious disease expert at UofL Health in Louisville, Kentucky. 'A sore throat is a symptom of this, but also fever and cough and fatigue, these are all symptoms as well,' Burns added. 'To sum it all up, the symptoms, including sore throat, are really no different. There's no increased intensity based on sore throat or anything like that,' added Burns. Here's how you can protect yourself from a COVID infection: Related: "People Are Creepy, And I'm Paranoid": 23 Safety Tips And Tricks Women Who Live Alone Do To Feel Safe And At Ease COVID tends to surge twice a year — once in the winter and once in the mid-to-late summer, Schaffner said. 'And so there has been a longstanding recommendation by the CDC's Advisory Committee on Immunization Practices that people who are at increased risk of getting severe COVID should actually get two COVID vaccinations a year. Obviously, one in the fall to prevent the winter increase, but another right now in order to help prevent serious disease during the late summer and early fall,' Schaffner said. This goes for people 65 and older, younger people with underlying chronic medical conditions and pregnant people, he said. 'The recommendation is take special precautions and get that extra dose, because if we get infected ... we get that extra protection and to help keep us out of the hospital,' Schaffner said. Wearing a mask in indoor spaces, social distancing, washing your hands often and increasing ventilation when possible are more ways to protect yourself from COVID and other respiratory viruses, too, said Burns. If you do get sick, there are treatments available. If you have any COVID symptoms, such as sore throat, fatigue, cough or fever, take a test to see if you have COVID. If you are infected, get in touch with your doctor, particularly if you're high-risk as there are treatments available, said Schaffner. It's important that you talk to your primary care provider as the guidance will vary depending on your age, underlying conditions and other risk factors. COVID is a miserable infection, Horn added. 'Over-the-counter meds help — Ibuprofen alternating with Tylenol, if you're able to take those ... there's no reason to be miserable,' Horn said. 'So, take the medicine that you are able to take to help,' she said. It's also important to stay hydrated when you're sick even if you do have a painful sore throat. A sore throat can make hydration feel like more of a chore, but it's important to drink water and herbal teas as dehydration can further irritate the dry membranes in your throat, Horn said. 'If you are sick, it's best to keep your germs to yourself,' said Horn. This means canceling the dinner plans, not going to the party and calling out of work if you can — if you can't, wearing a tight-fitting mask is key, Horn added. 'Preventing transmission is the biggest thing that we can do to help keep everybody healthy,' Horn article originally appeared on HuffPost. Also in Goodful: "It's Nice To Feel Wanted": Guys Are Sharing The Small Gestures Women Do That Make Them Weak At The Knees Also in Goodful: "I Can't Wait For This To Go Out Of Style": People Are Sharing Popular Modern Trends That Are Actually Pretty Toxic Also in Goodful: I Was Devastated When The Love Of My Life Died. Then I Started Seeing Signs I Couldn't Explain.
Medscape
a day ago
- Medscape
How ‘Patron Saint of Renegades' Transformed Cancer Care
Chinese American physician researcher Min Chiu Li, MD, liked breaking barriers and busting chops. Min Chiu Li, MD At a time when virtually every cancer researcher in the US was White, he landed a job at the National Cancer Institute (NCI) in the 1950s. As colleagues got along to get along, he made enemies galore. Then he went rogue, insisting on treating patients with chemotherapy beyond the point when their tumors had disappeared. The strategy turned out to be the right approach, even though Li lost his job over his failure to follow the rules. His work helped transform cancer therapy by showing how biomarkers tell the real story of how treatment is working. Li and his colleague Roy Hertz, MD, 'set the stage for a modern approach to chemotherapy, set the stage for hope,' Alan J. Hunter, MD, an internist at Oregon Health & Science University, Portland, Oregon, who studied Li's life for a 2003 report, told Medscape Medical News . Pushing Forward and Paying the Price In the mid-1950s, Li and Hertz were thrilled when antifolate treatment eliminated a young woman's metastatic tumors from choriocarcinoma, a rare type of cancer that develops from placenta cells after pregnancy. But Li was concerned because levels of a hormone linked to the cancerous cells didn't dwindle back to normal. 'Li became progressively obsessed with the number,' author and cancer physician Siddhartha Mukherjee, MD, DPhil, Columbia University, New York City, wrote in his landmark 2010 book The Emperor of All Maladies: A Biography of Cancer . Li refused to stop treating the patient despite fears that toxicity would hurt her. 'He kept on doing it' because the therapy worked, recalled Vincent DeVita, Jr, MD, a former director of the NCI and cancer therapy pioneer in his own right, in an interview. 'And he was told to leave at that point.' The stubborn researcher had been sacked. 'Li was already known to be a renegade, an iconoclast. This time, the NCI felt, he had gone too far,' Mukherjee wrote. But it turned out that treating cancer beyond the point when tumors are eliminated can be a wise approach. That's because it can kill off a hidden reservoir of tumor cells that are only revealed through biomarkers. The strategy worked in Li's patients. The ultimate result: The obstinance that cost him his job led to the first chemotherapeutic cure of cancer in adults. From China to Los Angeles, Chicago, and Beyond As colleague and childhood leukemia treatment pioneer Emil J. Freireich, MD, DSc, wrote in a 2002 remembrance, Li came to the US from China in 1947 for postgraduate studies in bacteriology and immunology at the University of Southern California, Los Angeles. However, Li couldn't return home due to the 1949 Communist revolution. He went on to jobs at Presbyterian Hospital in Chicago, the Sloan-Kettering Institute in New York City (now an arm of the Memorial Sloan Kettering Cancer Center), and then the NCI in Bethesda, Maryland. As Hertz recalled in a 1998 NCI oral history interview, he hired Li as a clinical associate after a colleague recommended him. 'Li had become a naturalized American citizen, and as soon as he became American, he was an MD, and as soon as he got his citizenship papers, he got drafted [in the Korean War], and when he got drafted, he wanted to stay out of the draft,' said in a 1998 NCI oral history interview. Mukherjee picks up the story: 'His current plan was to lie low in Bethesda until the war blew over.' In the mid-1950s, Li decided to test the antifolate methotrexate — which had recently become a breakthrough new treatment for leukemia — in a 24-year-old woman who'd developed lung metastases from choriocarcinoma. 'There was nothing to lose,' Li wrote in a 1979 report. 'To everyone's surprise,' he wrote, the woman — who was near death — survived the next 20 hours. She ultimately recovered after Li continued to treat her even though her tumors had vanished. 'The response was real: A metastatic, solid cancer had vanished with chemotherapy,' Mukherjee wrote. But the NCI wasn't impressed. 'They were calling this a spontaneous disappearance, probably an immunologic effect,' DeVita said. 'Everybody was pushing it off as something that was being done mostly by the body.' As DeVita recalled, Li tried the approach again with a second patient, and it worked again. 'He was told not to do it anymore because it was too dangerous. And he kept on doing it.' NCI Decides It's Seen Enough In his 1979 report, Li says he then went to the State University of New York in 1957, but he doesn't explain why he left the NCI. In fact, he'd been fired for failing to follow protocol when he treated patients past the point when their tumors were gone. But Li had discovered something vitally important about chemotherapy. According to Freireich, who died in 2021, Li realized that patients with metastatic choriocarcinoma 'required intensive systemic 'adjuvant' treatment despite the fact that they had no clinical evidence of disease. This has subsequently proven to be an extraordinarily important new principle in cancer treatment, ie, the treatment of patients who have no [physical] evidence of disease because of either tumor marker or other indirect evidence of a high probability of developing recurrent malignancies.' But the cautious brass at the NCI concerned itself with rules. 'Li was accused of experimenting on people,' Freireich told Mukherjee in a 2009 interview. 'But of course, all of us were experimenting…To not experiment would mean to follow the old rules — to do absolutely nothing. Li wasn't prepared to sit back and watch and do nothing. So he was fired for acting on his convictions, for doing something.' 'Irascible, Irritable, Pugnacious' Li, known as 'MC,' had tense relationships with some colleagues. 'He was very irascible, very irritable, pugnacious individual, got into fights with everybody…,' Hertz recalled in the oral history interview. 'He got into fights with a number of people, and I had to intervene a number of times.' According to Hertz, 'we attributed [this] to his loneliness and his privations' — Li had left his family in China — and 'I was the only one knew how to get along with Li.' But a lifelong rift apparently developed between the two colleagues. According to Hertz, Li believed he — Hertz — had taken the credit and won a major award for work that Li had done. 'I feel so bad about the whole thing,' Hertz said. 'I've had 40-odd clinical associates. He's the only one who does not honor me. The only one. And that hurts.' Racism may have played a role in isolating Li from his colleagues. Or perhaps it caused him to be resentful and bitter. Maybe both. DeVita, the former director of the NCI, said casual racism was common in mid-century. 'People would do it and do it casually, not even think they were doing something. That could be part of it,' said DeVita, 90, who once went to Li's home to meet him. Jonathan P. Yarris, MD, an emergency medicine physician in Oregon City, Oregon, who co-authored the 2003 report that examined the work of Hertz and Li, recalled that he interviewed Hertz and looked at old photos of his lab. 'There's usually one woman in the room, and sometimes, there's someone who's not White. I can only imagine what he heard in the hallways and how he was being slighted at every corner,' Yarris told Medscape Medical News . As for Li's stubbornness, 'having been a person who didn't always follow the rules, I was sympathetic,' DeVita said. 'Sure, he didn't follow the rules. But what people should have done is look at what happened. Nobody was seriously harmed by what he did, and the patients were actually cured.' More Medical Advances and a 'Renegade' Legacy Li conducted more pioneering research after the NCI imbroglio. He pioneered combination drug treatment for testicular cancer, and DeVita considers him to be the first to cure the disease. Patients were cured 'maybe 10% or 20% [of the time] when he tried it, not the 80%, 90% we get now, but it was significant enough to be mentioned in publications, and he usually wasn't,' DeVita said. 'He was generally not given the credit he deserved.' In 1972, Li won the Albert Lasker Medical Research Award, and colleague Freireich noted in his 2002 report that 'Dr Li remained active both in clinical research, laboratory research, patient care, and perhaps most important, teaching.' Later, Freireich wrote, 'one of his most important publications appeared…in which he showed that 5-fluorouracil given after colon cancer surgery could result in substantial improvement in long-term survival rate.' Li died in 1980, decades before several colleagues of his generation, from what Freireich calls 'a tragic illness.' As for his legacy, Yarris said that Li was 'ultimately vindicated.' And while his name isn't remembered as well as some other cancer researchers, Li's reputation survives at the NCI. There, Mukherjee wrote, he's the 'patron saint of renegades.'
